ING Group’s Nektar Therapeutics NKTR Stock Holding History

ING Group’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.98M	Hold	100,000	–	–	0.03%	285
2026 Q1	$7.2M	Hold	100,000	–	–	0.04%	236
2025 Q4	$4.23M	Buy	+100,000	New	+$5.6M	0.03%	302
2019 Q4	–	Sell	-729	Closed	-$199K	–	513
2019 Q3	$199K	Buy	+729	New	+$267K	0.01%	468
2019 Q2	–	Sell	-689	Closed	-$347K	–	809
2019 Q1	$347K	Buy	+689	New	+$408K	0.01%	564
2018 Q4	–	Sell	-342	Closed	-$313K	–	793
2018 Q3	$313K	Buy	+342	New	+$292K	0.01%	646

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ING Group's NKTR Position: Q2 2026 in Review

ING Group held its Nektar Therapeutics (NKTR) position steady in Q2 2026 at 100,000 shares worth $6.98M. The position accounts for 0.03% of the portfolio, ranked #285.

ING Group first reported a position in NKTR in Q3 2018 and has held it in 6 quarters since. The position peaked at $7.2M in Q1 2026. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

ING Group held 100,000 shares of Nektar Therapeutics worth $6.98M as of Q2 2026.
ING Group left its Nektar Therapeutics share count unchanged in Q2 2026.
Nektar Therapeutics made up 0.03% of ING Group's portfolio in Q2 2026, its #285 holding.
ING Group first reported a position in Nektar Therapeutics in Q3 2018 and has held it in 6 quarters since.
ING Group's Nektar Therapeutics position peaked at $7.2M in Q1 2026.
240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on ING Group's 13F filing for Q2 2026, filed 13 Aug 2026.